# A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

> **NCT07286032** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Patients With Chemotherapy-Induced Thrombocytopenia

## Interventions

- **DRUG:** Hetrombopag Olamine
- **DRUG:** Hetrombopag Olamine ；Hetrombopag Olamine Placebo

## Key facts

- **NCT ID:** NCT07286032
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-16
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286032, "A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07286032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*